A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR7390 Combined With SHR-1210 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Camrelizumab (Primary) ; SHR 7390 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 28 Feb 2018 Status changed from not yet recruiting to recruiting.
- 17 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
- 12 Jun 2017 New trial record